Skip to main content
Smart Investors Daily
OC

NASDAQ · OCS

Oculis Holding AG

Healthcare · Biotechnology

$7.44

Up+$0.05 (+0.68%)

Updated Nov 20, 2026, 9:42 AM

SID Score

3.0/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
1.09B
P/E ratio
-8.07
Dividend yield
0.00%
52-week range
$6.78 – $34.48
Volume
153.99K
Avg. volume
99.02K

Price performance · OCS

OCS price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 19, 2026

OCS closed at $7.44 after 21 trading sessions, down 8.03% for the selected period.

Last close
$7.44
Period change
-8.03%
Period low
$6.83
Period high
$8.26
Daily close
View OHLC price history
OCS OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 19, 2026$7.46$7.50$7.18$7.44153.99K
Nov 18, 2026$7.56$7.75$7.20$7.39311.56K
Nov 17, 2026$7.76$7.815$7.09$7.51239.99K
Nov 16, 2026$7.97$8.21$7.54$7.63211.17K
Nov 13, 2026$7.51$7.68$7.28$7.64183.98K
Nov 12, 2026$7.60$7.86$7.33$7.50299.11K
Nov 11, 2026$7.67$8.025$7.60$7.61227.36K
Nov 10, 2026$7.72$8.04$7.54$7.59266.85K
Nov 9, 2026$7.67$8.04$7.49$7.76339.86K
Nov 6, 2026$6.83$7.64$6.81$7.49404.09K
Nov 5, 2026$7.30$7.8542$6.78$6.83371.65K
Nov 4, 2026$7.60$7.89$6.80$7.28550.22K
Nov 3, 2026$7.72$7.87$7.29$7.63541.79K
Nov 2, 2026$8.38$8.539$7.66$7.71246.35K
Oct 30, 2026$8.19$8.84$8.19$8.26309.7K
Oct 29, 2026$8.09$8.53$8.09$8.24263.73K
Oct 28, 2026$7.80$8.05$7.72$7.98220.03K
Oct 27, 2026$7.92$8.145$7.68$7.83189.29K
Oct 26, 2026$7.88$8.025$7.65$7.96206.97K
Oct 23, 2026$8.04$8.07$7.82$7.90294.73K
Oct 22, 2026$7.77$8.3099$7.725$8.09427.89K

Latest OCS news

The latest Smart Investors Daily articles mentioning OCS.

OCS research

Overview

Company profile and research snapshot.

Company profile

Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$43.50
Implied upside
—
Analysts
—
OCS recent ratings
DateFirmRatingTarget
Nov 17, 2026HC Wainwright & Co.Buy—
Nov 4, 2026GuggenheimBuy—
Oct 23, 2026HC Wainwright & Co.Buy—
Sep 18, 2026HC Wainwright & Co.Buy—
Aug 14, 2026JP MorganOverweight—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Nov 16, 2026

Oculis Announces FDA IND Clearance Enabling Acceleration of Privosegtor Development Program in Acute Multiple Sclerosis Relapses

FDA IND clearance opens a new era for Oculis in neurology, initiating clinical development in acute MS relapses by building directly upon the positive Phase 2 ACUITY trial and ongoing PIONEER program in optic neuritis Oculis will host an R&D Day on December 8, 2026, to provide further updates on the development program for Privosegtor in acute MS relapses and the ongoing PIONEER program in optic neuropathies ZUG, Switzerland, November 16, 2026 -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Ocu

Yahoo · Nov 13, 2026

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities

ZUG, Switzerland, Nov. 13, 2026 (GLOBE NEWSWIRE) -- The attached notifications relate to the vesting and settlement of RSUs previously granted to directors of the Company. Attachments Notification of managers' transaction - Anthony Rosenberg - 13 November 2026 RSU vest Notification of managers' transaction - Christina Ackermann - 13 November 2026 RSU vest Notification of managers' transaction - Arshad Khanani - 13 November 2026 RSU vest Notification of managers' transaction - Robert Warner - 13

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.